Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Masahiro Suda"'
Autor:
Masahiro Suda, Koji Mikami
Publikováno v:
Frontiers in Marine Science, Vol 7 (2020)
The timing of the transition from growth to reproduction is essential for the regulation of the seaweed life cycle. Variable environmental conditions can stress seaweeds and promote trade-offs between their growth and reproduction. Here, we demonstra
Externí odkaz:
https://doaj.org/article/70d28e7f3057414eb9599b3827780dbd
Publikováno v:
Allergology International, Vol 55, Iss 4, Pp 403-410 (2006)
Background: A dry powder inhaler of KP-496 is currently in clinical development in Japan as an antiasthmatic agent. The aim of this study was to evaluate the in vitro pharmacological profile of KP-496. Methods: The antagonistic activities of KP-496 f
Externí odkaz:
https://doaj.org/article/b7201fcd9985402ba4d3bad4d46e6852
Autor:
Yoshihide Miyake, Masakazu Ishimura, Toshiaki Okuda, Tsutomu Nakamura, Yuzuru Matsumura, Masahiro Suda, Shigeo Kurokawa, Ryota Saito
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 23:425-431
Cysteinyl-leukotrienes (cysLTs) and thromboxane A(2) (TXA(2)) are important mediators in inflammatory lung diseases such as bronchial asthma and idiopathic pulmonary fibrosis (IPF). We examined the effects of inhaled KP-496, a novel dual antagonist o
Autor:
Junji Nakamura, Shouichi Ohga, Yoshiro Tsuji, Kohji Ueda, Masahiro Suda, Toshiro Hara, Tadamichi Yanagi, Eiichi Ishii
Publikováno v:
European Journal of Haematology. 38:63-66
Surface marker analysis of atypical cells, present at elevated levels in the peripheral blood of a 2-yr-old patient with familial erythrophagocytic lymphohistiocytosis (FEL), was performed with monoclonal antibodies. The atypical cells expressed T11,
Autor:
Hiroyuki Tanaka, Masakazu Ishimura, Yoshimasa Takahashi, Toshiaki Okuda, Hiroichi Nagai, Tsutomu Nakamura, Shota Tokuoka, Masahiro Suda, Shigeo Kurokawa
Publikováno v:
Pharmacology. 84:249-256
Aims: The aim of this study was to evaluate the effects of inhaled KP-496, a novel dual antagonist for cysteinyl leukotriene receptor 1 and thromboxane A2 receptor, on the allergic asthmatic responses in guinea pigs. Methods: Actively sensitized anim
Autor:
Yoshiyuki Hiyama, Takashi Maeda, Masakazu Ishimura, Shigeo Kurokawa, Masahiro Suda, Sayuri Kataoka
Publikováno v:
Biological and Pharmaceutical Bulletin. 32:1057-1061
Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play crucial roles in asthma. There is accumulating evidence to suggest contributions of cysteinyl leukotrienes (cysLTs) and thrombo
Autor:
Yoshiyuki Hiyama, Shigeo Kurokawa, Masakazu Ishimura, K Morizumi, Sayuri Kataoka, Masahiro Suda, Takashi Maeda
Publikováno v:
British Journal of Pharmacology. 153:669-675
Background and purpose: KP-496 is a novel dual antagonist for cysteinyl leukotriene receptor 1 (CysLT1) and thromboxane A2 (TXA2) receptor (TP). The aim of this study was to evaluate the pharmacological profile of inhaled KP-496 and its effects on ai
Publikováno v:
Allergology International, Vol 55, Iss 4, Pp 403-410 (2006)
Background A dry powder inhaler of KP-496 is currently in clinical development in Japan as an antiasthmatic agent. The aim of this study was to evaluate the in vitro pharmacological profile of KP-496. Methods The antagonistic activities of KP-496 for
Autor:
Akihiko Nomura, Sachiyo Suita, Hiroshi Ideguchi, Toshiro Hara, Hidetoshi Takada, Junko Kato, Masahiro Suda, Yukio Hattori, Shouichi Ohga
Publikováno v:
International Journal of Hematology. 78:329-334
We describe a 6-year-old girl and her mother with dominant β-thalassemia due to hemoglobin Hradec Kralove (Hb HK). Both patients presented microcytic anemia, jaundice, splenomegaly, cholelithiasis, and recurrent hemolytic bouts. Osmotic resistance t
Autor:
Shoichi Inaba, Akinobu Matsuzaki, Akihiko Nomura, Masahiro Suda, Kohji Ueda, Shouichi Ohga, Takeshi Kai
Publikováno v:
Pediatrics International. 38:317-321
In order to assess the clinical utility of granulocyte transfusions (GT), the stimulating effects of donor granulopoiesis for GT therapy were examined using either low dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) or dexameth